Dianthus Therapeutics Appoints Steven Romano to Board
Company Announcements

Dianthus Therapeutics Appoints Steven Romano to Board

Dianthus Therapeutics ( (DNTH) ) just unveiled an announcement.

Dianthus Therapeutics has welcomed Steven Romano, M.D., to its Board as a Class III director and Science and Technology Committee member, with immediate effect. He’ll be incentivized with an option for 22,000 shares of common stock, vesting over three years, alongside a yearly cash compensation of $40,000 for board duties and an additional $5,000 for committee work. Dr. Romano is also set to receive regular equity awards and will be covered under a standard indemnification agreement.

See more insights into DNTH stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyDianthus price target raised to $52 from $48 at Oppenheimer
TipRanks Auto-Generated NewsdeskDianthus Therapeutics Reports Q3 Progress and Financials
TheFlyDianthus reports Q3 EPS (74c), consensus (59c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App